140 related articles for article (PubMed ID: 33743485)
1. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma.
Hilmi M; Cros J; Puleo F; Augustin J; Emile JF; Svrcek M; Hammel P; Arsenijevic T; Van Laethem JL; Bachet JB; Nicolle R
Eur J Cancer; 2021 May; 148():171-180. PubMed ID: 33743485
[TBL] [Abstract][Full Text] [Related]
2. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.
Jamiyan T; Shiraki T; Kurata Y; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2020 Jun; 18(1):137. PubMed ID: 32571348
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methylation profiling.
Endo Y; Fujimoto M; Ito N; Takahashi Y; Kitago M; Gotoh M; Hiraoka N; Yoshida T; Kitagawa Y; Kanai Y; Arai E
J Cancer Res Clin Oncol; 2021 May; 147(5):1341-1354. PubMed ID: 33635431
[TBL] [Abstract][Full Text] [Related]
4. [Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].
Soriano-Izquierdo A; Adet AC; Gallego R; Miquel R; Castells A; Pellisé M; Nadal C; López-Boado MA; Piqué JM; Gascón P; Conill C; Bombí A; Fernández-Cruz L; Maurel J; Navarro S
Med Clin (Barc); 2009 Feb; 132(5):163-71. PubMed ID: 19211081
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.
Pokataev I; Kudaibergenova A; Artemyeva A; Popova A; Rumyantsev A; Podluzhny D; Kudashkin N; Fedyanin M; Tryakin A; Tjulandin S
J Gastrointest Cancer; 2019 Sep; 50(3):478-484. PubMed ID: 29675723
[TBL] [Abstract][Full Text] [Related]
6. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
7. Preoperative predictors for early recurrence of resectable pancreatic cancer.
Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
[TBL] [Abstract][Full Text] [Related]
8. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.
Kim J; Reber HA; Dry SM; Elashoff D; Chen SL; Umetani N; Kitago M; Hines OJ; Kazanjian KK; Hiramatsu S; Bilchik AJ; Yong S; Shoup M; Hoon DS
Gut; 2006 Nov; 55(11):1598-605. PubMed ID: 16682430
[TBL] [Abstract][Full Text] [Related]
9. KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.
Fu T; Guzzetta AA; Jeschke J; Vatapalli R; Dave P; Hooker CM; Morgan R; Iacobuzio-Donahue CA; Liu B; Ahuja N
Int J Cancer; 2013 Jun; 132(11):2502-9. PubMed ID: 23065691
[TBL] [Abstract][Full Text] [Related]
10. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing.
Chiam K; Mayne GC; Watson DI; Woodman RJ; Bright TF; Michael MZ; Karapetis CS; Irvine T; Phillips WA; Hummel R; Wang T; Pimlott LK; Marri S; Astill DS; Ruszkiewicz AR; Thompson SK; Hussey DJ
Ann Surg Oncol; 2018 Sep; 25(9):2731-2738. PubMed ID: 29987600
[TBL] [Abstract][Full Text] [Related]
11. PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential.
Wartenberg M; Centeno I; Haemmig S; Vassella E; Zlobec I; Galván JA; Neuenschwander M; Schlup C; Gloor B; Lugli A; Perren A; Karamitopoulou E
Eur J Cancer; 2016 Sep; 65():80-90. PubMed ID: 27475963
[TBL] [Abstract][Full Text] [Related]
12. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy.
Zhang Y; Frampton AE; Kyriakides C; Bong JJ; Habib N; Ahmad R; Jiao LR
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1063-71. PubMed ID: 22392075
[TBL] [Abstract][Full Text] [Related]
13. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
14. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
15. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.
Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R
Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564
[TBL] [Abstract][Full Text] [Related]
16. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
[TBL] [Abstract][Full Text] [Related]
17. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.
Motoi F; Murakami Y; Okada KI; Matsumoto I; Uemura K; Satoi S; Sho M; Honda G; Fukumoto T; Yanagimoto H; Kinoshita S; Kurata M; Aoki S; Mizuma M; Yamaue H; Unno M;
World J Surg; 2019 Feb; 43(2):634-641. PubMed ID: 30298281
[TBL] [Abstract][Full Text] [Related]
18. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
19. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]